Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:address |
12830 El Camino Real, Suite 400, San Diego, CA 92130, USA
|
| gptkbp:CEO |
gptkb:Stephen_R._Davis
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
neurological diseases
central nervous system disorders psychiatric diseases |
| gptkbp:foundedYear |
1993
|
| gptkbp:founder |
Mark R. Brann
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ACADIA Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:marketCap |
~$3 billion (2023)
|
| gptkbp:notable_drug |
NUPLAZID (pimavanserin)
|
| gptkbp:numberOfEmployees |
~500 (2023)
|
| gptkbp:product |
NUPLAZID
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
gptkb:Rett_syndrome
schizophrenia Alzheimer's disease psychosis Parkinson's disease psychosis |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ACAD
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.acadia-pharm.com/
|
| gptkbp:bfsParent |
gptkb:Baker_Bros._Advisors
|
| gptkbp:bfsLayer |
7
|